Holostem is the first biotechnological company entirely devoted to development, manufacture, registration and distribution of Advanced Therapies Medicinal Products (ATMPs) based on cultures of epithelial stem cells both for cell and gene therapy.Holostem Terapie Avanzate was born in 2008 as a university spin-off thanks to the profitable union among the Key Opinion Leaders like Michele De Luca and Graziella Pellegrini, the innovative spirit of the University of Modena and Reggio Emilia and the industrial know-how of Chiesi Farmaceutici S.p.A., a leading Italian pharmaceutical company.
On the 12th December 2023, Fondazione Enea Tech e Biomedical, a private foundation supervised by the Italian Ministry of Enterprises and Made in Italy, has formally completed the acquisition of Holostem S.r.l. including all assets and operations.
Holostem has a highly experienced management team, with a sound know-how derived from a long tenure both in business administration and in academic research, successfully applied since many years in translational medicine.
